Answers are grounded in this paper and cite their sources.
To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies. Profound and prolonged hypogammaglobulinemia was universal among responders, while immunoglobulin replacement was associated with 90% lower rates of grade 3-5 infections. See related commentary by Garfall and Stadtmauer, p. 427 . This article is featured in Selected Articles from This Issue, p. 419.
No takes yet. Share an insight, caveat, or question.
Lancman et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: